EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Evaluating Access to Prescription Medications in the Atopic Dermatitis Patient Population in the USA

Allison R Loiselle, Raj Chovatiya, Isabelle J Thibau, Jessica K Johnson, Michele Guadalupe, Wendy Smith Begolka

Dermatology and Therapy · 2024-07 · 14 (7) · 1811-1821

DOI: 10.1007/s13555-024-01205-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology and Therapy, online erschienen am 16.06.2024. Verfasst von Allison R Loiselle und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Eczema Association, 505 San Marin Drive, #B300, Novato, CA, 94945, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Despite advances in atopic dermatitis (AD) treatments, many patients face challenges obtaining medications. This study aimed to determine the frequency and causes of insurance coverage delays and denials for AD prescriptions and characterize the associated wait times and extent to which patients understand what to do when faced with a coverage issue. METHODS: This was a cross-sectional, observational study in which adult U.S. residents (aged 18+ years) with AD or caregivers of pediatric U.S. patients with AD (aged 0-17 years) completed an online survey (3 June-16 July 2021). RESULTS: Respondents (N = 978) were primarily adults with AD (81.8%), female (67.7%), and white (70.2%). There were 645 insurance delays or denials for AD prescriptions, with 48.1% (470/978) of respondents experiencing at least one delay/denial in the past year. Most delays/denials were for topical steroids (39.2%, 253/645), the most highly used prescription treatment class (83.9%, 821/978). However, the highest rate of delay/denials was for biologics, of which 43.6% (109/250) of all prescriptions faced a delay or denial. Denials were caused primarily by step therapy (27.6%) and delays by prior authorization (55.1%). Only 56.0% of respondents said they would know what to do if they faced an issue with AD prescription coverage. CONCLUSIONS: Patients with AD frequently experience insurance-related barriers to obtaining recommended therapies, and many do not know how to respond when these barriers arise. Strategies to improve timely therapeutic access are needed.

Schlagwörter

Stichwörter der Autor:innen

Atopic dermatitisEczemaPrescription accessPrior authorizationStep therapy

Autor:innen und Institutionen

  • National Eczema Association, 505 San Marin Drive, #B300, Novato, CA, 94945, USA.
  • Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
  • Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, 60064, USA.
  • Center for Medical Dermatology and Immunology Research, Chicago, IL, 60657, USA.
  • National Eczema Association, 505 San Marin Drive, #B300, Novato, CA, 94945, USA. wendy@nationaleczema.org.

Zitieren

APA

Loiselle, A. R., Chovatiya, R., Thibau, I. J., Johnson, J. K., Guadalupe, M., & Smith Begolka, W. (2024). Evaluating Access to Prescription Medications in the Atopic Dermatitis Patient Population in the USA. Dermatology and Therapy, 14(7), 1811-1821. https://doi.org/10.1007/s13555-024-01205-0

Vancouver

Loiselle AR, Chovatiya R, Thibau IJ, Johnson JK, Guadalupe M, Smith Begolka W. Evaluating Access to Prescription Medications in the Atopic Dermatitis Patient Population in the USA. Dermatology and Therapy. 2024;14(7):1811-1821. doi:10.1007/s13555-024-01205-0

BibTeX
@article{Loiselle2024,
  author = {Loiselle, Allison R and Chovatiya, Raj and Thibau, Isabelle J and Johnson, Jessica K and Guadalupe, Michele and Smith Begolka, Wendy},
  title = {Evaluating Access to Prescription Medications in the Atopic Dermatitis Patient Population in the USA},
  journal = {Dermatology and Therapy},
  year = {2024},
  volume = {14},
  number = {7},
  pages = {1811--1821},
  doi = {10.1007/s13555-024-01205-0}
}
Kostenlos starten →